Recently, mineralocorticoid receptor antagonists have shown considerable beneficial effects in hypertension [41], heart failure [42], metabolic syndrome [43], chronic kidney disease [44], atherosclerosis [45, 46], and vascular diseases [47]. This evidence concerns the gene NR3C2 and metabolic syndrome.